Company intelligence / Profile preview

ExactlyIT

Ownership: Private
Development stage: Other

Overview

EXACT Therapeutics has reported positive final results in its Phase 1 ACTIVATE trial for patients with liver metastases from colorectal cancer. Preclinical evidence supports utility in tumors and CNS disorders. The ACT® platform increases uptake of co-administered drugs into tumor tissue without damaging capillary walls and can cross the blood-brain barrier.

Therapeutic areas: NeurologyOncology
Industry: Therapeutic Medical Devices

Partnerships

GE Healthcare (manufacturing collaboration)Cordance Medical (strategic partnership announced September 2023)

Beyond the preview

Go deeper on ExactlyIT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExactlyIT.

Explore the full profile